leadf
logo-loader
viewAnteris Technologies Ltd

Admedus submits patent application and enters trading halt

The company's TAVR device is superior to its competitors.

Heart puzzle and hands of cardiac surgeon with surgical instruments
The company has also entered a trading halt pending news related to a debt facility

Admedus (ASX:AHZ) has submitted intellectual property (IP) applications relating to the development of a new transcatheter aortic valve replacement (TAVR) device.

The aortic valve is one of four valves in the human heart and a TAVR is a minimally invasive surgical procedure repairing the valve without removing the old, damaged valve.

The two separate pending patent applications in the U.S relate to the development and manufacture of a three-dimensional replacement heart valve.

It uses Admedus’ clinically superior proprietary ADAPT technology that requires minimal suturing; and a hydro-packaging system that will revolutionise the way TAVR products are assembled and distributed.

This marks the beginning of Admedus’ entry into the $3 billion global TAVR market, which is projected to be $5 billion by 2020.

Wayne Paterson, CEO, commented

“The benefits of our proprietary ADAPT technology and products are now scientifically proven beyond doubt.

“With published evidence of our durability, and clinically important remodelling and anti-calcification properties and more than nine years of data behind us, we are in a strong competitive position.

“The combination of our 3D valve, hydro-packaging and ADAPT technology would ensure the Admedus TAVR is far superior to any of its competitors – less expensive to produce, more efficient to use and offering greater health benefits to patients.”

Background

Admedus has two key revenue streams which totalled $22.3 million in FY17.

These include ADAPT®, the company's clinically superior regenerative tissue technology.

Sales for the ADAPT® portfolio of products for the period climbed 30% to $6.9 million

The second is the company's infusion business in Australia and New Zealand, where revenue increased 74% to $15.5 million.

The company expects to approach financial break even in the 2018 December quarter.

Trading halt entered

Admedus today entered a trading halt at its own request.

The halt was granted by the ASX pending an announcement regarding the finalisation of a structured debt facility.

The halt will remain in place until an announcement is made or until the commencement of trading on Thursday morning.

Quick facts: Anteris Technologies Ltd

Price: 3.94 AUD

ASX:AVR
Market: ASX
Market Cap: $23.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

1 week, 3 days ago

2 min read